by Risch F, Koschel M, Lenz B, Specht S, Hoerauf A, Hübner MP, Scandale I. Frontiers in Tropical Diseases 2022; doi: 10.3389/fitd.2022.982421
Summary: Originally developed for the veterinary market, oxfendazole is a lead macrofilaricidal candidate for the treatment of onchocerciasis and lymphatic filariasis. The authors of this study compared the efficacy of oxfendazole isomers with the commercially available racemic mixture Dolthene in a mouse model of filariasis using Litomosoides sigmodontis. Overall, the results suggest that both oxfendazole isomers have similar anti-filarial activity and do not support the development of a single isomer for future use in human patients.
